Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Altace Co-Promotion Lawsuit Spurs Question About King's Ability To Launch Nebivolol

This article was originally published in The Pink Sheet Daily

Executive Summary

An investment firm says Wyeth's lawsuit alleging King failed to meet its detailing obligations for Altace raises "concern" that King will lack the manpower needed to promote Mylan's beta blocker. Mylan says the King acquisition is the best strategy for maximizing nebivolol.

You may also be interested in...



Relationship With Wyeth "Much Improved" Despite Altace Lawsuit, King Says

King says its relationship with Wyeth is "much improved" despite an ongoing breach of contract lawsuit over the companies' co-promotion deal for Altace

Relationship With Wyeth "Much Improved" Despite Altace Lawsuit, King Says

King says its relationship with Wyeth is "much improved" despite an ongoing breach of contract lawsuit over the companies' co-promotion deal for Altace

Mylan/King Merger, GSK's Fluarix Expected To Highlight Oct. 28 Earnings Calls

Also reporting on Oct. 28 are Elan, ImClone and Medco. Final heavy week of quarterly pharma earnings updates include Oct. 27 reports by P&G, Merck KGaA and Novo Nordisk.

Related Content

Topics

UsernamePublicRestriction

Register

MT142313

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel